TNF-α blockers, such as infliximab, adalimumab and etanercept, are currently approved by the FDA for the treatment of chronic inflammatory diseases such as RA, Crohn’s disease and ankylosing spondylitis. This evidence concerns the gene TNF and Crohn disease.